Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing.
Tim Mackey, Matthew Nali, Meng Zhen Larsen, Zhuoran Li, Jiawei Li, Joshua Yang
Journal of medical Internet research June 30, 2025 DOI: 10.2196/64820 via PubMed
Summary
AI-generated from the abstractAfter a manufacturer's recall of Diamond Shruumz-branded mushroom-containing products in October 2024 due to hospitalizations, online vendors continued to market and sell the products. Before the recall, 4117 product listings were identified across social media, cannabis e-commerce websites, and search engine queries. Post-recall, 45 out of 67 domains (67.16%) still marketed the product, and simulated purchases succeeded on 15 of 45 domains (33.33%). The recall highlights ongoing challenges in enforcing online sales restrictions for new psychoactive substances, which appeal to younger audiences through flavored edible products.
Study at a glance
| Characteristics | Retrospective online market surveillance Qualitative Peer reviewed |
|---|---|
| Population | Online product listings for Diamond Shruumz-branded mushroom-containing products |
| Duration | June 22–27, 2024 (pre-recall surveillance); July 12, 2024 (post-recall simulated purchases) |
| Keywords | E-commerce Online monitoring Online surveillance Psychedelics Qualitative assessment |
| Citations | 1 |
| Key finding | Post-recall, 67.16% of domains continued to market Diamond Shruumz products, and 33.33% of simulated purchase attempts succeeded, indicating persistent online availability despite a manufacturer's recall. |
Abstract
Reports of hospitalization associated with Diamond Shruumz-branded mushroom-containing products in October 2024 led to a manufacturer's recall that restricted the sale, distribution, and accessibility of this new and emerging psychoactive product. This study seeks to assess the continuing online availability of a mushroom-containing edible product in a diverse e-commerce landscape, specifically aiming to identify and characterize its online availability before and after recall initiation. A retrospective online market surveillance of Diamond Shruumz products using structured and automated search queries was employed to identify online product marketing and availability. Online surveillance included the monitoring of multiple social media platforms, cannabis e-commerce websites, and search engine queries between June 22 and June 27, 2024, immediately preceding the manufacturer-initiated recall. Post-recall simulated purchases were then conducted on July 12, 2024, on platforms, websites and domains identified as continuing to actively market and sell the products through online product listings. Prior to product recall, a total of 4117 product listings across 1600 (38.86%) social media posts and user-generated comments, 11 (0.27%) cannabis e-commerce websites, and 2509 (60.94%) hyperlinks from internet search queries were generated for further content analysis. Review of online sources revealed 49 social media posts, 8 e-commerce shops, and 67 domains that were identified as actively marketing and selling products prior to recall. Post-recall, we identified 45 (67.16%) remaining domains that continued to market the product from these different online sources. Simulated purchases revealed that 15 (33.33%) domains successfully transacted test purchases and 30 (66.66%) transactions failed because of account verification or payment failure. The Diamond Shruumz recall exemplifies the ongoing challenge of unknown consumer harm associated with new and emerging substances marketed and sold on the internet, which is especially concerning as these products appeal to younger audiences with a variety of edible flavored products. While a recall was initiated and products became unavailable, our study found that post-recall online vendors continued to market and sell the products. This indicates that there are ongoing challenges to effectuate recalls and online enforcement in a diverse e-commerce landscape that can rapidly bring new and novel psychoactive substances to the market.